AKT1 and gastric cancer: Traditional mTOR inhibitors that block the PI3K/AKT/mTOR signaling pathway through mTORC1, including rapamycin and its analog everolimus, have not achieved satisfactory clinical results in a phase III clinical study of everolimus as a second or third-line treatment for advanced GC [86].